Tag Archives: Treatment

FDA Approves Qelbree (viloxazine) for the Treatment of ADHD

FDA Approves Qelbree (viloxazine) for the Treatment of ADHD ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity… Read More »

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment

A Brazilian man who last summer had no evidence of remaining HIV after more than 15 months off antiretroviral therapy once again had detectable viral load a few months later, according to a report last week at the virtual Conference on Retroviruses and Opportunistic Infections (CROI). Work is underway to determine whether he experienced viral… Read More »

The Buenos Aires patient: Argentinian woman controls HIV for at least 12 years after stopping treatment

An Argentinian woman, now in her 50s, has controlled HIV below the limits of detection since stopping HIV treatment due to side-effects in 2007, researchers from Buenos Aires and the US National Institutes of Health report. The woman no longer has antibodies to HIV and researchers found only a small number of cells containing HIV… Read More »

Hyperbaric Oxygen Treatment Reverses Signs of Aging

Hyperbaric oxygen treatment may be a practical method for slowing down the hands of time. At its foundation, aging represents a progressive loss of physiological capacity, researchers from Tel Aviv University and the Shamir Medical Center in Israel explained in the journal Aging.1 The biological deterioration leads to impaired functions and increased vulnerability to diseases,… Read More »

FDA Approves Sesquient (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients

FDA Approves Sesquient (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients PAOLI, Pa., — (BUSINESS WIRE) — November 9, 2020 – Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved Sesquient (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult… Read More »